A review published this June in the Journal of Endocrinological Investigation worked through what the TRAVERSE trial settled and what it did not. TRAVERSE randomized 5,246 men aged 45 to 80 who had confirmed low testosterone and elevated cardiovascular risk, followed them for a median of 3.2 years, and found no increase in major cardiovascular events on treatment, with a hazard ratio of 0.96. A European expert panel published its own position statement on the same evidence this year.

That is a real and useful answer to a question that hung over the field for a decade. It is also a narrower answer than the way testosterone is currently sold, because the trial studied men with a diagnosis, on physiological doses, under monitoring.

From the Lab to the Ledger

Testosterone falls gradually with age in most men, at a rate of roughly one percent a year after the forties. That decline on its own is not a disease. Clinical hypogonadism means consistently low morning testosterone measured more than once, together with symptoms, and ideally with an identified reason. The distinction matters because the men in TRAVERSE met that definition, and a large share of men receiving testosterone today do not.

What the review makes clear is that a clean result on the primary endpoint did not mean a clean result everywhere. Erythrocytosis, a thickening of the blood from too many red cells, was the most reproducible effect, appearing in 17 percent of treated men against 3.3 percent on placebo. That is not a footnote: it is the mechanism behind most of the other signals. Pulmonary embolism risk concentrated in the first six months, consistent with viscosity rising before anything else changes. Atrial fibrillation ran slightly higher without reaching statistical significance. Acute kidney injury did reach significance and has since been echoed in real-world cohorts.

The fracture result is the one people find hardest to believe. Bone density improved, and clinical fractures went up. The proposed explanation is behavioural rather than skeletal: men who feel stronger move more, and activity returns before tendons and balance catch up. Whatever the mechanism, it is a reminder that a better number on a scan is not automatically a better outcome for the person.

The other finding worth carrying into any consultation concerns men whose low testosterone is secondary to obesity or metabolic disease rather than to a problem with the testes or pituitary. In that group the guidance is to treat the metabolic picture first, because the hormone level often follows, and because replacing testosterone suppresses the body's own production and fertility for as long as it continues.

Bio-Pipeline Ledger

Testosterone replacement for confirmed organic hypogonadism at physiological doses: established, effective for the symptoms it targets, and now supported by cardiovascular safety data from a large randomized trial.

Cardiovascular safety in that population: demonstrated as non-inferior to placebo over roughly three years. Longer horizons remain untested.

Erythrocytosis monitoring: not optional. Hematocrit needs checking before starting and at intervals afterward, and it is the finding that most often forces a dose change or a pause.

Testosterone for age-related decline without a diagnosis: outside the tested indication. No trial supports treating a number that falls within the normal range for a man's age in the absence of symptoms and confirmation.

Prostate cancer risk: no increase was seen in TRAVERSE, which reverses a long-held assumption. Prostate monitoring is still part of standard follow-up.

Pellets, compounded creams and online direct-to-consumer prescribing without repeat morning measurements: the part of the market operating furthest from the evidence, and the route least likely to include the monitoring that makes treatment safe.

The Clinical Reality Check

What is established is that in men with confirmed hypogonadism and meaningful cardiovascular risk, physiological testosterone replacement did not raise the rate of heart attack, stroke or cardiovascular death across more than three years. For men who were refused treatment on that specific fear, this is a genuine change.

What is overstated is the leap from there to testosterone as a general-purpose vitality product. TRAVERSE was not a trial of energy, mood or body composition in men with ordinary levels, and its safety findings came with monitoring built in. A clinic that prescribes on one lab draw and a symptom questionnaire, and does not recheck hematocrit, is not running the intervention the trial validated.

The practical version is a short list to bring to a physician who does not sell the treatment: two separate morning measurements, a look for the cause rather than just the level, a baseline hematocrit and kidney function, a conversation about fertility if that matters, and a plan for what gets rechecked and when. If low testosterone turns out to sit downstream of weight, sleep apnea or alcohol, treating that first is not a delaying tactic. It is the step most likely to move the number and everything attached to it.